S-1/A: Elevai Labs Eyes Public Offering Amidst Nasdaq Compliance Concerns

Elevai Labs Inc. files an amendment to its Form S-1 registration statement for a public offering of common stock and warrants, aiming to raise capital while addressing Nasdaq listing deficiencies.

Summary

• Elevai Labs Inc. is planning a public offering involving shares of common stock, pre-funded warrants, Series A warrants, and Series B warrants.
• The company intends to offer up to 28,368,794 shares of common stock, along with corresponding warrants.
• The assumed public offering price is $0.282 per share, based on the last reported sale price on September 10, 2024.
• The Series A Warrants will have an exercise price of at least 250% of the Minimum Price as defined by Nasdaq and expire five years after the Initial Exercise Date.
• The Series B Warrants will also have an exercise price of at least 250% of the Minimum Price as defined by Nasdaq and expire two and a half years after the Initial Exercise Date.
• Univest Securities, LLC is acting as the exclusive placement agent for the offering.
• The company is also offering pre-funded warrants as an alternative to shares for purchasers who would exceed a 4.99% or 9.99% beneficial ownership threshold.
• The selling stockholders are offering an aggregate of 1,299,999 shares of common stock through a separate resale prospectus.
• The company intends to use the net proceeds for general corporate purposes, including working capital and investments.
• As of June 30, 2024, there is substantial doubt about the Companys ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document contains both positive and negative aspects. The company is expanding its product line and has promising research and development efforts. However, there are significant financial challenges and regulatory hurdles that need to be addressed. The sentiment is slightly negative due to the going concern issue and Nasdaq compliance concerns.

Positives

• The company is expanding its product line with the Elevai S-Series hair and scalp care system.
• Elevai Biosciences Inc. is developing EL-22, an engineered probiotic to address muscle loss during weight loss treatments.
• Elevai Research Inc. has a research partnership with Dalhousie University to study stem cell exosomes.
• The company has a comprehensive portfolio of intellectual property, including patents and trademarks.
• The company has a well-recognized and award-winning team and brand.

Negatives

• There is substantial doubt about the Companys ability to continue as a going concern.
• The company has a history of net losses.
• The company may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering.
• The company is no longer in compliance with Nasdaq's minimum stockholders equity requirement.
• The company has suspended sales in Canada after receiving correspondence from Health Canada indicating that our products are not compliant with applicable Canadian laws and regulations.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's revenues depend significantly on sales of its Elevai Post Treatment E-Series.
• The company faces intense competition from companies with greater resources.
• The company's products could be rendered obsolete by technological or medical advances.
• The company depends on third parties for manufacturing and formulation.
• The company may incur product liability claims.
• The company may be unable to continue to satisfy listing requirements of Nasdaq to maintain a listing of our common stock.

Future Outlook

The company intends to focus on growing revenue, utilizing clinical validation studies, R&D for new products, clinical development for Elevai Biosciences assets, pursuing acquisitions, and considering potential spin-offs.

Industry Context

The document highlights the growing market for medical aesthetic skincare products and the increasing consumer interest in cosmetic procedures. It also mentions the competitive landscape and the need for companies to innovate and differentiate themselves in the market.

Comparison to Industry Standards

• The document mentions several competitors in the medical aesthetic skincare market, including SkinCeuticals, SkinMedica, ZO Skin Health, and Alastin Skincare.
• It also discusses companies developing GLP-1 drugs for obesity, such as Novo Nordisk and Eli Lilly, and companies developing complementary treatments for muscle wasting, such as Versanis and Biohaven.
• The document cites market research reports from Statista, Research & Markets, and Verified Market Research to support its claims about market size and growth rates.
• The document references studies published in The New England Journal of Medicine and Int. J. Mol. Sci. to support its claims about obesity prevalence and the effects of EL-22.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a letter from Nasdaq stating that the company had failed to regain compliance with the Stockholders Equity Rule and our stock is subject to delisting.
• The company received a letter from Nasdaq stating that the common stock had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).

Related Party Transactions

• The company paid consulting fees to GB Capital Ltd., a company controlled by Graydon Bensler, Chief Financial Officer and Director.
• BWL Investments Ltd., a British Columbia Canadian Corporation owned and managed by Braeden Lichti and Hatem Abou-Sayed Tim Sayed, subscribed to promissory notes.
• The company entered into an advisory board agreement with Jeffery Parry, (an independent director to the Company as of June 1, 2023).
• The company entered into a consulting agreement with NorthStrive Companies Inc., a California Corporation owned and managed by Braeden Lichti.

Stakeholder Impact

• Shareholders may experience dilution as a result of future equity offerings or acquisitions.
• Shareholders may be affected by limited trading volume and price fluctuations of the common stock.
• Shareholders may be impacted by the company's ability to comply with Nasdaq listing requirements.
• Shareholders may be impacted by the company's ability to manage its growth and execute its business plan.

Next Steps

• File the Split Amendment and the Increase in Authorized Shares Amendment with the SEC.
• Effect the reverse stock split and increase the total number of authorized shares.
• Submit an Investigational New Drug (IND) application in 2025 for EL-22.
• Initiate clinical trials in the U.S. to evaluate EL-22 in combination with GLP-1 receptor agonists in obesity.
• Expand the production capacity of products by March 31, 2025.

Key Dates

Keywords

public offering, warrants, common stock, Elevai Labs, prospectus, exosomes, skincare, biopharmaceutical, Nasdaq, EL-22